SCHEMBL7062984

SCHEMBL7062984

Cc1ccc(S(=O)(=O)ON(N=Cc2cc(F)cc(F)c2[N+](=O)[O-])C(=N)N)cc1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.33
ALDH1A1 P00352 7/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MEN1 O00255 5/20 0.32
KMT2A Q03164 5/20 0.32
LMNA P02545 7/20 0.32
MCOLN3 Q8TDD5 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 2/20 0.32
AKR1B1 P15121 1/20 0.31
MAPK1 P28482 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7062256 0.84 ALDH1A1 (0.41) MAPTALDH1A1CYP2C9CYP2C19CYP1A2
SCHEMBL7062982 0.83 CYP2D6 (0.34) MAPTALDH1A1CYP2D6MEN1KMT2A
SCHEMBL7062981 0.83 CYP2D6 (0.34) MAPTALDH1A1CYP2D6MEN1KMT2A
SCHEMBL7062996 0.81 MAPT (0.38) MAPTALDH1A1CYP2C9CYP2C19CYP1A2
SCHEMBL7065388 0.81 ATM (0.38) MAPTALDH1A1CYP2C9CYP2C19CYP1A2
SCHEMBL7062480 0.80 ALDH1A1 (0.47) MAPTALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL7065577 0.79 ALDH1A1 (0.37) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL7066729 0.79 ALDH1A1 (0.53) MAPTALDH1A1CYP2C9CYP2C19CYP1A2
SCHEMBL7065963 0.79 MAPT (0.38) MAPTALDH1A1CYP2C9CYP1A2MEN1
SCHEMBL7066015 0.78 KMT2A (0.38) MAPTALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313461-A2 THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS Melacure Therapeutics AB (SE) 2003-05-28 EP claimed
WO-2002011715-A2 THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS MELACURE THERAPEUTICS AB (SE) 2002-02-14 WO claimed